Hamlet Pharma has participated in a number of recent events, presenting highligts from the promising clinical studies and our future strategy. With this newsletter, we…
Read More
Hamlet Pharma AB (publ) (”Hamlet Pharma” eller ”Bolaget”) emitterade under 2021 teckningsoptioner av serie TO 3 B och TO 4 B. Varje teckningsoption ger rätt…
Hamlet Pharma enters a new business development phase involving multiple cancer indications and markets. Based on the successful outcomes of our clinical trial program, we…
Hamlet Pharma has recently delivered its 18-month report to the Euro- pean Union’s Horizon 2020 program. In their response, the EU states that the project…
Pressmeddelande Hamlet Pharma deltar på Stockholm Corporate Finance 14e Life Science Kapitalmarknadsdagar den 8 – 9 mars 2022. Catharina och Mats presenterar den 8 mars…
Hamlet-Pharma-Newsletter-Dose-escalationDownload
Read More
MON, JAN 17, 2022 12:15 CET Hamlet Pharma has previously reported the successful completion of a Phase I/II study using a 1.7 mM dose of…
FRI, JAN 14, 2022 14:59 CET To continue Hamlet Pharma’s drug development process towards Phase III trials and future commercialization, it is essential to expand…
Press Release, Lund December 18, 2019 Hamlet Pharma is on track with its plans to engage in a clinical trial of Alpha1H for the treatment…
BioWorld. November 6, 2019 By Cormac Sheridan – DUBLIN – Hamlet Pharma AB is about to embark on the next phase in the clinical development…
Aktieägarna i Hamlet Pharma AB, 556568-8958, kallas härmed till årsstämma torsdagen den 21 november 2019 kl. 17.30 i Gamla Börssalen, Malmö Börshus med adress Skeppsbron…
At the end of July 2019, Hamlet Pharma announced the successful completion of the Phase I/II bladder cancer study. We now provide more detailed information…